openPR Logo
Press release

Cataract Pipeline: Emerging Non-Surgical Solutions and Leading Companies Shaping the Future of Cataract Treatment | DelveInsight

05-12-2025 04:07 PM CET | Health & Medicine

Press release from: DelveInsight

Cataract Pipeline

Cataract Pipeline

The therapeutic landscape for Cataract, the leading cause of blindness globally, is undergoing a paradigm shift as researchers and biopharmaceutical companies explore non-surgical and disease-modifying alternatives to conventional cataract extraction surgery. Advances in molecular biology, oxidative stress modulation, and crystallin protein stabilization have opened new avenues for pharmacological intervention. Companies like Nacuity Pharmaceuticals, CGeneTech, and Plex Pharmaceuticals are pioneering efforts to develop novel agents aimed at delaying, halting, or reversing cataract progression.

DelveInsight's "Cataract - Pipeline Insight, 2025" offers a comprehensive analysis of ongoing clinical and preclinical R&D, spotlighting emerging drug candidates, novel mechanisms of action, and innovative delivery systems. From anti-aggregation agents and antioxidants to topical formulations and gene therapy candidates, the pipeline reflects a robust and diversified approach to tackling cataracts beyond surgery.

This report provides a detailed overview of investigational therapies across development phases, highlighting trends in administration routes, formulation innovations, and geographic trial distribution. It also delves into the critical unmet needs, strategic collaborations, regulatory designations (e.g., orphan drug and fast track), and scientific breakthroughs that are poised to redefine the cataract treatment landscape in the coming years.

Interested in learning more about the current treatment landscape and the key drivers shaping the cataract pipeline? Click here: https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cataract Pipeline Report
• DelveInsight's cataract pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for cataract treatment.
• The leading cataract companies include Nacuity Pharmaceuticals, CGeneTech, Melt Pharmaceuticals, Plex Pharmaceuticals, and others are evaluating their lead assets to improve the cataract treatment landscape.
• Key cataract pipeline therapies in various stages of development include NPI 002, CGT 1507, Research programme: ocular therapeutics, and others.
• In March 2025, Bausch + Lomb (NYSE/TSX: BLCO) voluntarily recalled its enVista intraocular lenses following reports of unexplained complications.
• In November 2024, Melt Pharmaceuticals announced positive topline results from its Phase III trial of MELT-300, a non-IV, non-opioid sedation tablet for cataract surgery, meeting FDA-agreed criteria for regulatory submission.
• In June 2024, Alcon (SIX/NYSE: ALC) announced that its UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) received FDA 510(k) clearance, marking the first innovations from its Unity portfolio.

Request a sample and discover the recent breakthroughs happening in the cataract pipeline landscape @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cataract Overview
Cataracts occur when the lens of the eye becomes cloudy, limiting light reaching the retina and impairing vision. They develop slowly over time and may not cause symptoms in the early stages, but without treatment, they worsen and can lead to blindness. In New Zealand, cataracts are a leading cause of vision loss in older adults, primarily due to aging, but can also result from medical conditions, eye injuries, genetics, or medications. Cataracts can also be congenital or develop in children due to infections or trauma.

Common symptoms include cloudy or blurry vision, light sensitivity, difficulty with night driving, and changes in vision or eye prescriptions. If cataracts are suspected, a referral to an ophthalmologist for further examination is recommended. Cataracts can be classified by location, with nuclear cataracts affecting the center of the lens causing significant vision impairment, while cortical cataracts may cause less noticeable issues. Early-stage cataracts may be managed with glasses and better lighting, but surgery is required when cataracts interfere with daily life. Cataract surgery is typically done as a day-stay procedure under local anesthesia with mild sedation.

Find out more about cataract medication @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cataract Treatment Analysis: Drug Profile
NPI 002: Nacuity Pharmaceuticals
Nacuity Pharmaceuticals has developed an intravitreal implant prototype containing NPI-002, a small antioxidant molecule designed to slow cataract progression, along with a proprietary injector. The company has completed non-clinical testing, obtained HREC approval, and plans to begin a Phase 1/2 clinical trial in Australia for NPI-002 in the fourth quarter of 2021.

CGT 1507: CGeneTech
CGT 1507 is a small molecule targeting proteolytic enzymes. Currently in the pre-clinical stage, this drug is being developed for the treatment of cataracts.

Research Programme: Ocular Therapeutics - Plex Pharmaceuticals
Plex Pharmaceuticals is developing CAP 1160, a small molecule targeting HSP27 heat-shock protein modulators, as part of its ocular therapeutics program. The molecule aims to enhance the chaperone-like activity (CLA) of alpha-crystallin (AC), a key protein in the eye lens, to reverse, slow, or prevent cataract formation. By improving AC's CLA, Plex aims to protect damaged lens proteins and prevent aggregation, which is critical for maintaining lens transparency and preventing cataract development.

Learn more about the novel and emerging cataract pipeline therapies @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cataract Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Cataract Pipeline Report
• Coverage: Global
• Key Cataract Companies: Nacuity Pharmaceuticals, CGeneTech, Plex Pharmaceuticals, and others.
• Key Cataract Pipeline Therapies: NPI 002, CGT 1507, Research programme: ocular therapeutics, and others.

Dive deep into rich insights for drugs used for cataract treatment; visit @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cataract Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cataract Pipeline Therapeutics
6. Cataract Pipeline: Late-Stage Products (Phase III)
7. Cataract Pipeline: Mid-Stage Products (Phase II)
8. Cataract Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cataract Pipeline: Emerging Non-Surgical Solutions and Leading Companies Shaping the Future of Cataract Treatment | DelveInsight here

News-ID: 4011265 • Views:

More Releases from DelveInsight

PH-ILD Market Size in the 7MM was ~USD 3 Billion in 2024 and is projected to increase during the forecast period (2025-2034), estimates DelveInsight
PH-ILD Market Size in the 7MM was ~USD 3 Billion in 2024 and is projected to inc …
DelveInsight's "Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of PH-ILD, historical and forecasted epidemiology, as well as the PH-ILD market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Discover Key Insights into the Pulmonary Hypertension associated with Interstitial Lung Disease Market with DelveInsight's In-Depth Report @ Pulmonary Hypertension associated with
Sensorineural Hearing Loss Clinical Trials Analysis 2025: Emerging Regenerative Approaches, Gene Therapies, and Neuromodulation Aim to Restore Auditory Function | DelveInsight
Sensorineural Hearing Loss Clinical Trials Analysis 2025: Emerging Regenerative …
DelveInsight's "Sensorineural Hearing Loss Clinical Trials Analysis, 2025" describes a rapidly evolving pipeline targeting both restoration of inner-ear structures and symptomatic improvement. Ongoing programs span hair cell regeneration via small molecules and biologics, AAV- and non-viral gene-replacement or gene-editing strategies for monogenic deafness, cell-based therapies (supporting synaptic reconnection), and cochlear neuromodulation advancements to augment residual hearing. Trials increasingly pair novel delivery methods (e.g., intracochlear, round-window) with precision patient selection based
Cell and Gene Therapy in Parkinson's Disease Clinical Trials Analysis 2025: Disease-Modifying Strategies and Circuit-Level Restorations Aim to Slow Progression and Improve Motor/Non-motor Outcomes | DelveInsight
Cell and Gene Therapy in Parkinson's Disease Clinical Trials Analysis 2025: Dise …
DelveInsight's "Cell and Gene Therapy in Parkinson's Disease - Clinical Trials Analysis, 2025" highlights a diversified development landscape pursuing symptomatic relief and disease modification. Programs include dopamine-restorative cell implants, neuroprotective gene therapies targeting α-synuclein aggregation or neuroinflammation, and circuit-targeted gene delivery to rebalance basal ganglia networks. Trials incorporate advanced delivery (stereotactic infusion), standardized imaging and molecular biomarkers, and combination strategies pairing cell/gene therapy with neuromodulation. Pivotal and late-phase trials focus on
Staphylococcal Infections Clinical Trials Analysis 2025: New Antibacterials, Anti-virulence Agents, and Host-Directed Therapies Aim to Overcome Resistance and Improve Clinical Cure Rates | DelveInsight
Staphylococcal Infections Clinical Trials Analysis 2025: New Antibacterials, Ant …
DelveInsight's "Staphylococcal Infections Clinical Trials Analysis, 2025" outlines a focused effort to tackle antibiotic resistance and severe invasive disease. Active programs include novel small-molecule antibacterials with activity against MRSA, anti-virulence and quorum-sensing inhibitors, monoclonal antibodies targeting toxins and surface proteins, and host-directed immunotherapies to enhance clearance. Trials cover a range of indications from complicated skin and soft tissue infections to bacteremia and prosthetic-joint infections, with increasing attention on combination regimens

All 5 Releases


More Releases for Cataract

Transformative Trends Impacting the Cataract Surgery Devices And Equipment Marke …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Cataract Surgery Devices And Equipment Market Size By 2025? The market size for cataract surgery devices and equipment has shown a consistent growth trend in recent years. It is projected to increase from $13.97 billion in 2024 to $14.52 billion in 2025, exhibiting a compound
Cataract Surgery Devices Market - Innovation Meets Precision: Elevate Cataract S …
Newark, New Castle, USA: The "Cataract Surgery Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Cataract Surgery Devices Market: https://www.growthplusreports.com/report/cataract-surgery-devices-market/7846 This latest report researches the industry structure,
Intraocular Lens Implants for Cataract Market is Driven by the Increasing Incide …
The proposed Intraocular Lens Implants for Cataract Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes detailed analysis of market drivers, restraints, technological advancements & competitive landscape along with various micro & macro factors influencing the market dynamics. The Intraocular Lens Implants for Cataract Market
Potential Opportunities of Cataract Surgical Devices Market
The global cataract surgical devices market size is projected to reach USD 9.98 billion by the end of 2026. The high prevalence of cataract disorders will open up a huge potential for market growth. According to a report published by Fortune Business Insights, titled "Cataract Surgical Devices Market Size, Share & Industry Analysis, By Product Type (Phacoemulsification Systems, Femtosecond Laser, Intraocular Lenses, Ophthalmic Viscoelastic Devices & Other Consumables), By End-user
Cataract Surgery Devices Market Opportunity Analysis, 2018-2026
Cataract surgery devices are used during the surgical procedures to treat cataract, which is an eye disorder that causes clouding of the lens leading to defects in vision. Cataract is one of the most widespread disease causing blindness and it reduces vision ability. Cataract is often encountered to develop slowly and affect either one or both the eyes. Although cataract does not interfere with the eyesight in the early stages, it
Cataract Market Professional Survey Report 2017
Global Cataract Market: Snapshot The incrementing demand in the global cataract market is a reflection of growing geriatric population, as people aged over 60 years frequently develop conditions wherein eyes have reduced elasticity and in turn affects the normal functioning. The market for cataract is also expected to gain from awareness programs such as VISION 2020, launched by the WHO and the International Agency for the Prevention of Blindness. Primarily, there are